F-STAR THERAPEUTICS, INC.
Babraham Research Campus
Cambridge, CB22 3AT, United Kingdom
August 19, 2021
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: David Gessert
F-star Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 13, 2021
File No. 333-258783
Dear Mr. Gessert:
With respect to the above-referenced Registration Statement on Form S-3 (the Registration Statement), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of F-star Therapeutics, Inc. (the Company), that the Securities and Exchange Commission (the Commission) accelerate the effective date of the Registration Statement to Monday, August 23, 2021, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Megan Gates or William Hicks of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
|Very truly yours,|
|F-STAR THERAPEUTICS, INC.|
|Chief Financial Officer|
Megan N. Gates, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
William C. Hicks, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.